The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Value Is Anticipated For The Pheochromocytoma Market Over The Period 2026–2030?
The pheochromocytoma market size has demonstrated consistent growth in recent years. It is anticipated to expand from $3.13 billion in 2025 to $3.24 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 3.5%. Historically, this growth can be attributed to various factors such as enhancements in adrenal tumor diagnosis, the availability of surgical treatment options, increasing clinical awareness regarding endocrine tumors, the expansion of imaging-based diagnostic tools, and a rise in the reporting of hypertension-related conditions.
The pheochromocytoma market is projected to experience consistent expansion over the upcoming years, with its valuation anticipated to reach $3.87 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 4.6%. This projected growth is driven by several factors, including the increasing integration of precision oncology approaches, a surge in investments dedicated to rare tumor research, the broadening scope of genetic screening programs, the wider application of targeted therapies, and progress in radionuclide treatment methodologies. Key trends foreseen during this period encompass the increased uptake of sophisticated imaging diagnostics, a growing reliance on genetic testing for identifying tumors, a rising inclination towards less invasive surgical interventions, the spread of targeted radionuclide therapies, and a heightened emphasis on detecting the disease at earlier stages.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12909&type=smp
Which Major Factors Are Driving The Expansion Of The Pheochromocytoma Market?
The projected expansion of the pheochromocytoma market is primarily fueled by the rising incidence of tumors. These are atypical cellular growths, categorized as either benign (non-cancerous) or malignant (cancerous). The increasing prevalence of tumors and cancers underscores the necessity for heightened medical awareness, precise diagnostic methods, and customized treatment plans for effective management of desmoid pheochromocytoma. As a rare adrenal gland tumor, pheochromocytoma contributes to the overall tumor incidence by augmenting the count of diagnosed endocrine neoplasms, particularly as enhanced detection and awareness bring more cases to light. Supporting this, the American Cancer Society, a US-based non-profit cancer advocacy organization, reported in January 2023 that cancer cases escalated to 1,958,310 in 2023. Consequently, the rising rate of tumor incidence is set to propel the growth of the pheochromocytoma market moving forward.
How Is The Pheochromocytoma Market Divided Into Its Major Segments?
The pheochromocytoma market covered in this report is segmented –
1) By Type: Adrenal Pheochromocytoma, Extra-Adrenal Pheochromocytoma
2) By Treatment: Medication, Surgery, Radionuclide Treatment, Other Treatments
3) By Diagnosis: Laboratory Tests, Imaging Tests, Genetic Testing
4) By End Users: Hospitals, Clinics, Research And Academic Institutes, Other End Users
Subsegments:
1) By Adrenal Pheochromocytoma: Unilateral Adrenal Pheochromocytoma, Bilateral Adrenal Pheochromocytoma
2) By Extra-Adrenal Pheochromocytoma: Sympathetic Paraganglioma, Parasympathetic Paraganglioma
What Trends Are Affecting The Expansion Of The Pheochromocytoma Market?
Leading companies in the pheochromocytoma market are actively engaged in clinical trials to assess novel treatment approaches, therapies, and medications for pheochromocytoma, which is fostering the creation of more efficacious and precise treatments and ultimately enhancing patient outcomes. For instance, in May 2025, Merck & Co., a US-based biopharmaceutical company, obtained Food and Drug Administration (FDA) approval for Welireg (belzutifan). This oral therapy is designated for adults and pediatric patients (= 12 years) with locally advanced pheochromocytoma or paraganglioma (PPGL). The treatment works by selectively inhibiting hypoxia-inducible factor 2 alpha (HIF 2a), a key molecular driver in many PPGL tumors, thereby assisting in the reduction of tumor progression. Additionally, Welireg is formulated as a convenient oral therapy, offering a targeted, non-surgical pathway for the long-term management of advanced pheochromocytoma and paraganglioma (PPGL) in eligible patients.
Who Are The Prominent Organizations Shaping The Pheochromocytoma Market?
Major companies operating in the pheochromocytoma market are Pfizer Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Plc, Abbott Laboratories, Takeda Pharmaceutical Company Limited, Merck KGaA, Teva Pharmaceutical Company Limited, Mylan N.V., Bausch Health Companies Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Apotex Inc., Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Endo International plc, Exelixis Inc., Lupin Limited, Lantheus Holdings Inc., Curium Pharma, ANI Pharmaceuticals Inc., Jubilant Cadista Pharmaceuticals Inc., WellSpring Pharmaceutical Corporation, HRA Pharma SE
Read the full pheochromocytoma market report here:
https://www.thebusinessresearchcompany.com/report/pheochromocytoma-global-market-report
Which Region Currently Holds The Largest Share Of The Pheochromocytoma Market?
North America was the largest region in the pheochromocytoma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pheochromocytoma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Pheochromocytoma Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=12909&type=smp
Browse Through More Reports Similar to the Global Pheochromocytoma Market 2026, By The Business Research Company
Pheochromocytoma Global Market Report
https://www.thebusinessresearchcompany.com/report/pheochromocytoma-global-market-report
Paroxysmal Nocturnal Hemoglobinuria Pnh Global Market Report
Pharyngitis Treatment Global Market Report
https://www.thebusinessresearchcompany.com/report/pharyngitis-treatment-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model